Table 1.
Cohort characteristics
| Age | mean 49.6 years (range 19–85) |
|---|---|
| Variable | N |
| Sex | |
| Male | 45 |
| Female | 52 |
| WHO grade | |
| I | 4 |
| II | 11 |
| III | 15 |
| IV | 70 |
| Histotype | |
| Astrocytic | 91 |
| Oligodendroglial | 9 |
| IDH1 status | |
| Wild-type | 66 |
| Mutant | 34 |
| MGMT status | |
| Methylated | 45 |
| Unmethylated | 49 |
| Unknown | 6 |
| Recurrent | |
| Yes | 38 |
| No | 62 |
| TMZ treatment | |
| Pre | 67 |
| Post | 33 |
| Hypermutated | |
| Yes | 9 |
| No | 91 |
| TOTAL | 100 |
N = 100 tumors from 96 patients (two females each had two tumors in this cohort, and one male had three tumors). See Additional file 1: Table S1 for further information on each tumor. TMZ temozolomide